Negative Feedback Inhibition of NFATc1 by DYRK1A Regulates Bone Homeostasis

被引:59
|
作者
Lee, Youngkyun [2 ,3 ]
Ha, Jeongim [2 ,3 ]
Kim, Hyung Joon [2 ,3 ]
Kim, Yeun-Soo [1 ]
Chang, Eun-Ju [2 ,3 ]
Song, Woo-Joo [1 ]
Kim, Hong-Hee [2 ,3 ]
机构
[1] Inje Univ, Inst Brain Sci & Technol, Grad Program Neurosci, Pusan 614735, South Korea
[2] Seoul Natl Univ, Dept Cell & Dev Biol, BK21 Program, Seoul 110749, South Korea
[3] Seoul Natl Univ, DRI, Seoul 110749, South Korea
关键词
FACTOR-KAPPA-B; DOWN-SYNDROME; DUAL-SPECIFICITY; TRANSGENIC MICE; OSTEOCLAST DIFFERENTIATION; MENTAL-RETARDATION; RECEPTOR ACTIVATOR; FUNCTIONAL-LINK; PROTEIN-KINASES; YOUNG MEN;
D O I
10.1074/jbc.M109.042234
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
DYRK1A is a serine/threonine kinase that has been linked to mental retardation associated with Down syndrome. In the present report, we describe a previously unknown role for DYRK1A in bone homeostasis. The protein expression of DYRK1A increased during osteoclast differentiation. In vitro studies in osteoclasts revealed that DYRK1A inhibited osteoclastogenesis. Whereas DYRK1A phosphorylated and inhibited the osteoclastogenic transcription factor NFATc1, forced expression of NFATc1 induced DYRK1A expression, suggesting a negative feedback loop. Transgenic mice overexpressing DYRK1A by the extent of the increased gene dosage in Down syndrome exhibited significantly reduced bone mass despite the decreased osteoclastogenesis, which is reminiscent of osteoporotic bone phenotype in Down syndrome patients. In these mice, attenuated osteoblast differentiation and function in the presence of extra DYRK1A overrode the effect of impaired osteoclastogenesis. However, impeded osteoclastogenesis in DYRK1A transgenic mice was proven to be beneficial in protecting bone loss induced by inflammation or estrogen deficiency. These results provide novel insight into the role for DYRK1A in bone homeostasis as well as in bone destructive diseases, in which modulation of DYRK1A might be used as a strategy to treat unregulated bone resorption.
引用
收藏
页码:33343 / 33351
页数:9
相关论文
共 50 条
  • [41] Recent insights into the function of DYRK1A
    Becker, Walter
    FEBS JOURNAL, 2011, 278 (02) : 222 - 222
  • [42] DYRK1A and cognition: A lifelong relationship
    Arbones, Maria L.
    Thomazeau, Aurore
    Nakano-Kobayashi, Akiko
    Hagiwara, Masatoshi
    Delabar, Jean M.
    PHARMACOLOGY & THERAPEUTICS, 2019, 194 : 199 - 221
  • [43] Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells
    Recasens, Ariadna
    Humphrey, Sean J.
    Ellis, Michael
    Hoque, Monira
    Abbassi, Ramzi H.
    Chen, Brianna
    Longworth, Mitchell
    Needham, Elise J.
    James, David E.
    Johns, Terrance G.
    Day, Bryan W.
    Kassiou, Michael
    Yang, Pengyi
    Munoz, Lenka
    CELL DEATH DISCOVERY, 2021, 7 (01)
  • [44] The Omnipresence of DYRK1A in Human Diseases
    Deboever, Estelle
    Fistrovich, Alessandra
    Hulme, Christopher
    Dunckley, Travis
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (16)
  • [45] Skeletal health in DYRK1A syndrome
    Otte, Elysabeth D.
    Roper, Randall J.
    FRONTIERS IN NEUROSCIENCE, 2024, 18
  • [46] DYRK1A kinase regulates mTOR signaling via modulating the TSC complex
    Menon, Vijay R.
    Litovchick, Larisa
    CANCER RESEARCH, 2015, 75
  • [47] Negative Feedback Control of Osteoclast Formation through Ubiquitin-mediated Down-regulation of NFATc1
    Kim, Jung Ha
    Kim, Kabsun
    Jin, Hye Mi
    Song, Insun
    Youn, Bang Ung
    Lee, Seoung-Hoon
    Choi, Yongwon
    Kim, Nacksung
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (08) : 5224 - 5231
  • [48] The role of DYRK1A in neurodegenerative diseases
    Wegiel, Jerzy
    Gong, Cheng-Xin
    Hwang, Yu-Wen
    FEBS JOURNAL, 2011, 278 (02) : 236 - 245
  • [49] DYRK1A targets Pol II
    Andrea Du Toit
    Nature Reviews Molecular Cell Biology, 2015, 16 (3) : 127 - 127
  • [50] Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox
    Gu, Wen
    Wang, Zhongqun
    Sun, Zhen
    Bao, Zhengyang
    Zhang, Lili
    Geng, Yue
    Jing, Lele
    Mao, Xiang
    Li, Lihua
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2020, 75 (03) : 200 - 207